Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibrx Biosciences (INBX) Amortization of Deferred Charges (2023 - 2025)

Inhibrx Biosciences (INBX) has disclosed Amortization of Deferred Charges for 3 consecutive years, with $638000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Amortization of Deferred Charges changed N/A to $638000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $1.8 million, a 45.74% decrease, with the full-year FY2024 number at $2.1 million, down 57.85% from a year prior.
  • Amortization of Deferred Charges was $638000.0 for Q3 2025 at Inhibrx Biosciences, up from $626000.0 in the prior quarter.
  • In the past five years, Amortization of Deferred Charges ranged from a high of $1.2 million in Q4 2023 to a low of $533000.0 in Q1 2025.
  • A 3-year average of $906857.1 and a median of $823000.0 in 2024 define the central range for Amortization of Deferred Charges.
  • Biggest YoY gain for Amortization of Deferred Charges was 23.94% in 2025; the steepest drop was 57.09% in 2025.
  • Inhibrx Biosciences' Amortization of Deferred Charges stood at $1.2 million in 2023, then tumbled by 34.0% to $823000.0 in 2024, then fell by 22.48% to $638000.0 in 2025.
  • Per Business Quant, the three most recent readings for INBX's Amortization of Deferred Charges are $638000.0 (Q3 2025), $626000.0 (Q2 2025), and $533000.0 (Q1 2025).